<span id="midArticle_start"/>May 5 (Reuters) - Morphosys AG
<span id="midArticle_0"/>* Q1 positively impacted by one-off effects relating tomor202
<span id="midArticle_1"/>* Group revenues increased to eur 70.4 million (q1 2014: eur15.9 million)
<span id="midArticle_2"/>* Earnings before interest and taxes (EBIT) amounted to eur52.8 million
<span id="midArticle_3"/>* Q1 net profit 40.9 million eur
<span id="midArticle_4"/>* Product pipeline comprised a total of 95 therapeuticantibodies, including 23 clinical programs
<span id="midArticle_5"/>* Now expects revenues for 2015 financial year in amount ofeur 101 million to eur 106 million
<span id="midArticle_6"/>* Now expects earnings before interest and taxes (ebit) ofapproximately eur 9 million to eur 16 million in 2015Source text for Eikon: Further company coverage:
<span id="midArticle_7"/>
<span id="midArticle_0"/>* Q1 positively impacted by one-off effects relating tomor202
<span id="midArticle_1"/>* Group revenues increased to eur 70.4 million (q1 2014: eur15.9 million)
<span id="midArticle_2"/>* Earnings before interest and taxes (EBIT) amounted to eur52.8 million
<span id="midArticle_3"/>* Q1 net profit 40.9 million eur
<span id="midArticle_4"/>* Product pipeline comprised a total of 95 therapeuticantibodies, including 23 clinical programs
<span id="midArticle_5"/>* Now expects revenues for 2015 financial year in amount ofeur 101 million to eur 106 million
<span id="midArticle_6"/>* Now expects earnings before interest and taxes (ebit) ofapproximately eur 9 million to eur 16 million in 2015Source text for Eikon: Further company coverage:
<span id="midArticle_7"/>
via Smart Health Shop Forum http://ift.tt/1E3jSDN
No comments:
Post a Comment